EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Neoadjuvant Intra-arterial Cytoreductive Chemotherapy Improves Outcomes in Lacrimal Gland Adenoid Cystic Carcinoma

Philippos Apolinario Costa iD, David T Tse, Pasquale Benedetto

The Oncologist · 04.03.2024 · 29 (3) · 263-269

DOI: 10.1093/oncolo/oyad346 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, online erschienen am 16.01.2024. Verfasst von Philippos Apolinario Costa und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Oncology, Yale University, New Haven, CT, USA. Hauptthemen laut MEDLINE: Carcinoma, Adenoid Cystic, Lacrimal Apparatus, Lacrimal Apparatus Diseases, Eye Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lacrimal gland adenoid cystic carcinoma (LGACC) has historically been associated with a poor prognosis even with localized disease, with a survival of 56% at 5 years. In 1988, we treated the first patient with neoadjuvant intra-arterial cytoreductive chemotherapy (IACC). Since then, we have used this protocol as the standard approach. We aim to analyze the outcomes of patients with LGACC treated with the protocol and compare them to a population-based cohort to assess if IACC can improve survival.

Methods

We prospectively assessed all non-metastatic patients with LGACC treated with IACC at a single institution between 1988 and 2021. For a comparison group, we identified all non-metastatic patients with LGACC treated with excision from the Surveillance, Epidemiology, and End Results (SEER) registry. We calculated disease-specific survival using the Kaplan-Meier and Cox proportional-hazards modeling methods.

Results

Thirty-five non-metastatic patients with LGACC treated with IACC were identified at a single institution, and 64 patients with non-metastatic LGACC treated with excision were identified in the SEER database. The 5- and 10-year disease-specific survival rates for patients treated with IACC were 84% (95%CI 71-97) and 76% (95%CI 60-92), respectively. While the 5- and 10-year disease-specific survival rates for the population-based cohort were 72% (95%CI 62-82) and 46% (95%CI 32-60). The survival analysis favored IACC, with a 60% lower risk of death (HR: 0.4; 95%CI 0.2-0.9).

Conclusion

IACC improves disease-specific survival in comparison to a population-based cohort treated with excision. Additional patients treated with IACC at multiple institutions are required to provide further external validity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Adenoid CysticLacrimal ApparatusLacrimal Apparatus DiseasesEye NeoplasmsHead and Neck NeoplasmsHumansNeoadjuvant TherapyCytoreduction Surgical ProceduresRetrospective Studies

Stichwörter der Autor:innen

intra-arterial chemotherapylacrimal gland adenoid cystic carcinomaneoadjuvantoutcomes

Autor:innen und Institutionen

  • Department of Medicine, Division of Oncology, Yale University, New Haven, CT, USA.
  • Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, USA.
  • Department of Medicine, Division of Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.

ORCID-Profile: Philippos Apolinario Costa

Zitieren

APA

Costa, P. A., Tse, D. T., & Benedetto, P. (2024). Neoadjuvant Intra-arterial Cytoreductive Chemotherapy Improves Outcomes in Lacrimal Gland Adenoid Cystic Carcinoma. The Oncologist, 29(3), 263-269. https://doi.org/10.1093/oncolo/oyad346

Vancouver

Costa PA, Tse DT, Benedetto P. Neoadjuvant Intra-arterial Cytoreductive Chemotherapy Improves Outcomes in Lacrimal Gland Adenoid Cystic Carcinoma. The Oncologist. 2024;29(3):263-269. doi:10.1093/oncolo/oyad346

BibTeX
@article{Costa2024,
  author = {Costa, Philippos Apolinario and Tse, David T and Benedetto, Pasquale},
  title = {Neoadjuvant Intra-arterial Cytoreductive Chemotherapy Improves Outcomes in Lacrimal Gland Adenoid Cystic Carcinoma},
  journal = {The Oncologist},
  year = {2024},
  volume = {29},
  number = {3},
  pages = {263--269},
  doi = {10.1093/oncolo/oyad346}
}
Kostenlos starten →